TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Burst Suppression Anesthesia for Treatment of Severe Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Diagnosis of Major Depressive Disorder (MDD) or bipolar Disorder (I or II, most recent episode must be depression~  * Failed at least 2 anti-depressant treatments and no ECT in past 6 months~ * Age between 18-55 years~ * BMI \< 35~ * Hamilton Rating Scale for Depression (HSRD) score \> 18~ * Quick Inventory of Depression Scale (QIDS) score \> 10.~Exclusion Criteria:~* • Diagnosis of primary psychotic disorder, dysthymia, or personality disorder~  * Significant pre-morbid cognitive impairment~ * Hypertension and current use of ACE inhibitor or AR blocker medications~ * Symptomatic coronary artery disease or congestive heart failure~ * History of transient ischemic or neurologic signs during the past year~ * History of or susceptibility to malignant hyperthermia~ * Contraindication to isoflurane or propofol anesthesia (as determined by anesthesiologist)~ * Diabetes requiring insulin~ * Poor kidney function~ * Chronic use of benzodiazepines or opioids~ * Individuals incompetent to provide consent (e.g. catatonic, psychotic).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: EXPERIMENTAL): Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Legal adult age and able to give Informed Consent.~* Adult subjects with a diagnosis of ADPKD. A diagnosis of ADPKD (age 18 or 20-50) required several cysts in each kidney (3 if by sonography, 5 if by CT or MRI) in those with a family history of ADPKD and 10 cysts (by any radiologic method) in each kidney and exclusion of other cystic kidney diseases if there was no family history.~* Willingness to comply with reproductive precautions, if female.~* Estimated creatinine clearance ≥ 60 mL/min. Estimated from serum creatinine during screening using Cockcroft-Gault with correction for gender and race, where possible.~* Rapidly progressive kidney growth (total volume ≥ 750 cc) by magnetic resonance imaging (MRI) at randomization.~Exclusion Criteria:~* Prior exposure to tolvaptan or other experimental PKD therapies.~* Currently taking medication for purpose of affecting PKD cysts.~* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods.~* In the opinion of the study investigator or sponsor may present a safety risk or confound study objectives.~* Patients who are unlikely to adequately comply with study procedures.~* Patients having contraindications to MRI.~* Patients taking medications or having any illnesses likely to affect ADPKD outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (upon awakening and 9 hours later) orally for 36 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Participants that are currently or previously enrolled in the core study (AAAE0544 \[NCT01199614\]) and have maintained uninterrupted therapy with recombinant human parathyroid hormone (rhPTH(1-84)) (transient interruptions of up to 1 month continuously off treatment may be allowed).~* Signed and dated informed consent form (ICF).~* Adult men and women 18 to 85 years of age.~* History of hypoparathyroidism for at least 12 months prior to rhPTH(1-84) treatment, defined by the requirement for supplemental calcium and/or active vitamin D to maintain serum calcium along with an undetectable or insufficient Parathyroid hormone (PTH) concentration.~* Able to perform daily subcutaneous (SC) self-injections of study medication (or have designee perform injection).~* Willingness and ability to understand and comply with the protocol. Women must agree to pregnancy testing and acceptable methods of contraception, as detailed in the protocol.~Exclusion Criteria~* The participant is treated or has been treated with any investigational drug, aside from rhPTH(1-84), within 30 days of consent.~* As assessed by the investigator, the participant has any safety or medical issues that contraindicate participation in the study.~* The participant and/or the participant's parent(s) or legally-authorized representative(s) are unable to understand the nature, scope, and possible consequences of the study.~* The participant is unable to comply with the protocol, example, uncooperative with protocol schedule, refusal to agree to all of the study procedures, inability to return for evaluations, or is otherwise unlikely to complete the study, as determined by the investigator or the medical monitor.~* The participant is pregnant or lactating.~* Participants who are at increased baseline risk for osteosarcoma such as participant with Paget's disease of bone or unexplained new elevations of alkaline phosphatase, participants with hereditary disorders predisposing to osteosarcoma or participants with a prior history of external beam or implant radiation therapy involving the skeleton.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- rhPTH(1-84) (Type: EXPERIMENTAL): Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Males and females between 18 and 75 years of age, inclusive~2. Diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria~3. Body mass index from 18 to \<45 kg/m2~4. Consent to use a medically acceptable method of contraception~5. Willing and able to provide written informed consent~Major Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating~2. Moderate or severe sleep apnea on the baseline PSG.~3. Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~4. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria~5. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator~6. History of bariatric surgery within the past year or a history of any gastic bypass procedure~7. Presence or history of significant cardiovascular disease~8. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness~9. Use of any medications that could affect the evaluation of cataplexy~10. Received an investigational drug in the past 30 days or five half-lives (whichever is longer)~11. Previous exposure to or participation in a previous clinical trial of JZP-110 (ADX-N05, R228060, YKP10A)~12. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 75 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 150 mg JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 300 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- Placebo (Type: PLACEBO_COMPARATOR): Once Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is currently taking a statin medication for the treatment of high cholesterol~* Participant has an LDL-C level that is greater than or equal to 100 mg/dl and less than or equal to 190 mg/dl~Exclusion Criteria:~* Women who are pregnant or nursing, or women who intend to become pregnant~* Participant has any condition, situation, or is currently taking any medication that might pose a risk to the participant or interfere with participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: drug
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has been diagnosed with histologically or cytologically confirmed solid cancer~* Starting with first cycle of chemotherapy of moderate emetogenic risk, which does not include a combination of anthracycline plus cyclophosphamide~* Age ≥ 18~* WHO ≤ 1~* Patient is able to understand and speak Dutch~Exclusion Criteria:~* Patient with nausea and/or vomiting in 48 hours before start of chemotherapy treatment~* Patient submitted to concomitant radiotherapy or submitted to radiotherapy 15 days before start of chemotherapy or planned to receive radiotherapy during 8 days after administration of chemotherapy~* Patient with concomitant severe comorbidy, such as: o Intestinal obstruction o Active peptic ulcer o Hypercalcemia o Uncontrolled diabetes mellitus o Pheochromocytoma o Tardive dyskinesia o Epilepsia o Active infective diseases o Brain - or leptomeningeal metastases o Psychiatrical disorders o Parkinsonism~* Current use of corticosteroids (similar to prednisone ≥ 10 milligrams per day)~* Current alcohol abuse~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- metoclopramide (Type: ACTIVE_COMPARATOR): None
- dexamethason (Type: ACTIVE_COMPARATOR): None
- palonosetron (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Provide informed consent and authorization to disclose protected health information~* Have habitual contact lens corrected visual acuity in each eye of at least 20/30~* Willing to comply with protocol~* Wear soft daily contact lenses for total wear time of at least 4 hours a day and at least 4 days a week on average over at least a 30 day period before enrollment~Exclusion Criteria:~* Have any uncontrolled systemic disease that in the investigator's opinion could be expected to interfere with the study, for example, conditions associated with dry eye disease~* Pregnant by self-report~* Active ocular conditions: infection, allergic conjunctivitis, severe eyelid inflammation including anterior blepharitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Twice Daily Application of Bruder compress (Type: EXPERIMENTAL): Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
- Once Daily Application of Bruder compress (Type: EXPERIMENTAL): Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
- Twice Daily Application of warm washcloth (Type: SHAM_COMPARATOR): Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 1-year history of migraine with or without aura consistent with a diagnosis.~* Age of the participant at the time of migraine onset \<50 years.~Exclusion Criteria:~* Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine.~* Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy.~* History of an inadequate response to \>4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine.~* Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching atogepant tablets orally once daily for 12 weeks.
- Atogepant 10 mg (Type: EXPERIMENTAL): Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
- Atogepant 30 mg (Type: EXPERIMENTAL): Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
- Atogepant 60 mg (Type: EXPERIMENTAL): Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SmarToyGym: Smart Detection of Atypical Toy-oriented Actions in At-risk Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants exhibiting typical development between 3 months and 11 months of age who score in the low-risk category on the Bayley Infant Neurodevelopment Screener (BINS), score greater than 85 on all sub-scales of the Bayley Scale of Infant Development (BSID-II), have no history of significant cardiac, orthopedic or neurological condition and have a gestational age at least 37 weeks.~* Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age, score in the moderate or high risk categories on the BINS, and score an 85 or less on the motor sub-scales of the BSID-II.~* Exclusion Criteria:~* Infants outside age range of 3-11 months

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 11 Months
- Healthy Volunteers: t

Study Arms:
- Infants (Type: EXPERIMENTAL): Two populations will be involved in testing in the SmarToyGym: 1. Infants exhibiting typical development between 3 months and 11 months of age 2 . Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. written informed consent;~2. ≥18 years of age;~3. a bacterial infection of the skin with a lesion size area of at least 75 cm2;~4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;~5. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).~Exclusion Criteria:~1. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;~2. infected diabetic foot ulcers;~3. infected decubitus ulcers;~4. necrotizing fasciitis or gangrene;~5. uncomplicated skin or skin structure infection;~6. infections associated with a prosthetic device;~7. suspected or confirmed osteomyelitis;~8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iclaprim (Type: EXPERIMENTAL): iclaprim 80 mg intravenous every 12 hours
- vancomycin (Type: ACTIVE_COMPARATOR): vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Repeatability in Hyperpolarized 3-Helium With MRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must be between the ages of 18 and 90~* must have a Body Mass Index (BMI) of \< 32 and weigh \< 200 lbs.~Exclusion Criteria:~* if female, must not be pregnant or breastfeeding~* must not have any metal objects in or on their body including body piercings that cannot be easily removed, bullets, metallic fragments or slivers in eyes, skin, etc., pacemaker or defibrillation, aneurysm clips, cochlear implants, coronary stents, or neurostimulation.~* must not have a history of claustrophobia, panic disorders, anxiety attacks, atrial fibrillation, uncontrolled high blood pressure, frequent ventricular ectopic rhythm, hemodynamic instability, kidney dysfunction or heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Group One: Prone MRI Scans (Type: EXPERIMENTAL): Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
- Group Two: Supine MRI scans (Type: ACTIVE_COMPARATOR): Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete